A Randomized, Placebo- And Sitagliptin-Controlled Trial of the Safety and Efficacy of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Japanese Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism - United Kingdom
doi 10.1111/dom.12988
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients With Type 2 Diabetes: The EDIT Randomized Trial

PLoS ONE
Multidisciplinary
2015English

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2006English

Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2017English

Efficacy and Safety of Repaglinide Added to Sitagliptin in Japanese Patients With Type 2 Diabetes: A Randomized 24-Week Open-Label Clinical Trial

Endocrine Journal
EndocrinologyMetabolismDiabetes
2016English

Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Hydroxychloroquine in Patients With Type 2 Diabetes Mellitus

Global Journal of Endocrinological Metabolism
2018English

Combination Therapy With Once-Weekly Glucagon Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: A Case Series

Pharmacy Practice
Pharmaceutical SciencePharmacy
2019English

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology
Pharmacology
2018English

Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy